Introduction
Gastric cancer is one of the most fatal malignancies worldwide. It is estimated that a total of 952,000 new gastric cancer cases and 723,000 related deaths occurred in 2012, making gastric cancer the fifth most common malignancy and the third leading cause of cancer-related deaths in the world. 1 Although the promotion of endoscopic screening has helped to decrease gastric cancer mortality, the survival rate remains poor. Many patients are diagnosed at an advanced stage, as chemotherapy regimens are largely ineffective. As the first-line treatment for advanced gastric cancer, palliative chemotherapy can slightly prolong the median survival time to 7-10 months, but the 5-year survival rate is only 5%-15%. 2 Moreover, chemo-related toxicity and resistance limited efficiency and further use of chemotherapy. With an improved understanding of the molecular mechanisms of gastric cancer, medical scientists have made substantial efforts to identify novel and effective methods for targeted therapies. However, except for trastuzumab, which targets gastric cancer with ERBB2 amplification, no other targeted therapy has been approved for gastric cancer thus far.
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Jin et al Phosphiotidylinositol-3-kinase (PI3K)/Akt signaling plays a vital role in regulating cell proliferation and survival in cancer. 3 The activation of the PI3K/Akt pathway is initiated by the binding of growth factors to activate receptor tyrosine kinases, which phosphorylates PI3K. Activated PI3K catalyzes the phosphorylation of phosphotidylinositol-4, 5-bisphosphate (PIP2) to PIP3. As a second messenger, PIP3 is essential for the translocation of Akt to the plasma membrane, where it is activated by the phosphorylation of Thr308 and Ser473. 4 Akt, also known as protein kinase B, consists of three isoforms, Akt 1 /PKα, Akt 2 /PKβ, and Akt 3 / PKγ, 5 and is critical in phosphorylating a wide array of downstream substrates involved in cell growth, survival, apoptosis, and drug sensitivity. 6, 7 The aberrant activation of PI3K/Akt pathway is an important driver of cancer progression and chemoresistance, which may be mediated by various mechanisms including mutations in phosphoinositide-3-kinase catalytic α-polypeptide (PIK3CA), 8 loss or inactivating mutations of the tumor suppressor gene phosphatase and tesin homolog (PTEN), 9 overexpression of Akt/PKB isoforms, 6 and the amplification of upstream receptors.
In gastric cancer, the PI3K/Akt pathway is frequently activated. Analysis of gastric cancer tissue by immunohistochemistry revealed that Akt and p-Akt expression levels were detected in 74% and 78% of the tumors, respectively. 10 Their expression levels were found to be associated with tumor aggressiveness, depth of invasion, lymph node metastasis, and multidrug resistance. 11, 12 Moreover, p-Akt expression may predict the clinical outcome of gastric cancer patients. 10 Thus, the PI3K/Akt pathway is an attractive therapeutic target for gastric cancer.
MK-2206, a new allosteric inhibitor of pan-Akt kinase, has been reported to augment the efficacy of conventional antitumor therapies in various cancer cells. [13] [14] [15] [16] [17] MK-2206 is well tolerated in a phase I trial with evidence of Akt-signaling blockade. 18 However, only limited studies have assessed MK-2206 effect on gastric cancer. Thus, the present study was undertaken to investigate the preclinical activity of MK-2206 in gastric cancer cells and the potential synergetic effect of MK-2206 in combination with two conventional chemotherapeutics, doxorubicin and 5-fluorouracil (5-FU).
Materials and methods reagents and antibodies
MK-2206 (Selleck Chemicals, Houston, TX, USA) was dissolved in dimethylsulfoxide at 10 mM and stored at -80°C. 5-FU purchased from InvivoGen (San Diego, CA, USA) was dissolved in phosphate-buffered saline (pH 7.4), and doxorubicin hydrochloride purchased from HisunPharm (Taizhou, People's Republic of China) was dissolved in sterile distilled water. Both drugs were stored at -4°C and shielded from light.
Rabbit anti-Akt, p-Akt (Ser473), caspase-9, caspase-7, caspase-3, poly ADP ribose polymerase (PARP), cleaved caspase-3, cleaved caspase-7, and cleaved caspase-9 were purchased from Cell Signaling Technology (Danvers, MA, USA). β-Actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
cell culture
Human gastric cancer cells, SGC-7901 and MKN45, were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, People's Republic of China) and maintained at 37°C in RPMI-1640 medium (Genom, Hangzhou, People's Republic of China) supplemented with 10% fetal bovine serum, 100 μg/mL ampicillin, and 0.1 mg/mL streptomycin, in a humidified atmosphere containing 5% CO 2 and 95% air. 
cell viability assays
Determination of combination index
Combination index (CI) was used to quantitatively determine the synergy between the drugs in combined chemotherapies. CI values were calculated based on the median-effect method of Chou 19 as follows:
where (A comb ) and (B comb ) represent the concentrations of drug A and drug B that achieve a specific effect when used in combination, and (A) and (B) represent the concentrations of drug A and drug B that achieve the same effect as in the individual monotherapy. CI =1 indicates an additive effect, CI ,1 indicates a synergistic effect, and CI .1 indicates an antagonistic effect.
Western blotting Equal amounts of proteins were loaded on 8%-12% Tris-Glycine gels and transferred onto polyvinylidene fluoride membranes, which were then blocked with 5% fat-free milk in phosphatebuffered saline with 0.1% Tween 20 for 1 hour and blotted with the specific primary antibodies. The membranes were then washed with phosphate-buffered saline with 0.1% Tween 20 and incubated with the secondary antibodies. The protein-antibody complexes were then visualized using an enhanced chemiluminescence kit (Biological Industries, Cromwell, CT, USA).
statistical analysis
Data with normal distribution and homogeneity of variance were analyzed with one-way analysis of variance (ANOVA). Otherwise, nonparametric test was used. P,0.05 was considered statistically significant. All statistical analyses were performed with GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA, USA).
Results
effect of MK-2206 on the proliferation and apoptosis of gastric cancer cell lines
We first examined the antiproliferative effect of MK-2206 as a single agent in gastric cancer cells SGC-7901 and MKN45 ( Figure 1A Figure 1B) . Except for the growth inhibition, MK-2206 could also result in gastric cancer cell death. With increased MK-2206 dose, SGC-7901 cells gradually showed morphological changes such as shrinkage, aggregation, and spherical and micronucleation (Figure 2A) , generally indicating the process of apoptosis. Further Annexin-V-FITC/PI assay confirmed the related apoptosis in gastric cancer cells caused by MK-2206 augmentation. It induced dose-dependent apoptosis, with significant increase in the early, late, and total apoptosis. However, no statistical significance was found until the concentration reached 16 μM (P,0.05; one-way ANOVA followed by Tukey's tests) ( Figure 2B and C). These data suggest that MK-2206 is a potent apoptosis inducer in gastric cancer cells. (Figure 3 ; Table 2 ). Referring to the combination index in Table 2 , we observed a synergistic interaction between MK-2206 and doxorubicin (or 5-FU) in both SGC-7901 and MKN45 cells. Also, MK-2206 co-treatment with either doxorubicin or 5-FU was far superior to that of single drug treatments.
Western blotting was performed to evaluate the inhibitory effect of MK-2206 on Akt phosphorylation in SGC-7901 cells. As shown in Figure 4A , 1 μM MK-2206 could completely inhibit the phosphorylation of Akt at Ser473 without affecting total Akt levels. The inhibitory effect was observed within 12 hours and lasted for at least 48 hours (Figure 4) . On the other hand, we found that doxorubicin or 5-FU alone may increase the expression of p-Akt in a dose-dependent manner. However, the co-treatment with 1 μM MK-2206 could completely abrogate the chemotherapy-induced activation of Akt ( Figure 4B ). Similarly, this inhibitory effect of MK-2206 could start as early as 3 hours and remained stable within 24 hours ( Figure 4C ). Since 1 μM MK-2206 was able to inhibit the activation of Akt, we chose this relatively low concentration to further explore the effect of MK-2206 on the chemotherapeutic sensitivity of SGC-7901. The cleavage of caspase-9, caspase-7, caspase-3, and PARP was detected using Western blotting. Compared with doxorubicin (0.1, 0.2, 0.8 μM) or 5-FU (12, 24, 96 μg/mL) alone, the addition of 1 μM MK-2206 could enhance the apoptosis induction in SGC-7901 cells ( Figure 5 ). The expression of cleaved caspase-3, caspase-7, caspase-9, and PARP was significantly higher when MK-2206 was combined with 0.8 μM doxorubicin or 96 μg/mL 5-FU.
Discussion
In this study, we tested the therapeutic potential of MK-2206 in gastric cancer. Our data showed that MK-2206 effectively abrogated Akt signaling and attenuated the growth of gastric cancer cells. This finding is consistent with previous reports that MK-2206 could effectively inhibit the growth of various cancer cells such as thyroid, nasopharyngeal, colorectal, and lung in vitro and in vivo. 13, 16, 17, [22] [23] [24] However, single-agent MK-2206 appeared to have a limited effect on the proliferation of gastric cancer cells at clinically relevant concentrations. At low micro-molar concentrations, the growth inhibitory effect did not exceed 30% in either SGC-7901 (2-8 μM) or MKN45 cells (2-4 μM) . Similar results have also demonstrated that the viability of gastric cancer cell lines AGS, SNU-1, and SNU-16 decreased until the concentration of MK-2206 was .6 μM. complex signaling networks in human cancers, the blockage of a single target molecule or pathway might be insufficient, since other molecules or alternative pathways may compensate for the inhibited component. 13 Moreover, it was found in other types of cancer cells that treatment with MK-2206 induces autophagy, which might be a protective mechanism against MK-2206-induced cytotoxicity. [26] [27] [28] Therefore, the mechanism that mediated the sensitivity of gastric cancer cells to MK-2206 merits further investigation.
The activation of PI3K/Akt pathway plays an important role in the biology of cancers such as tumorigenesis, tumor metastasis, and the resistance to conventional chemotherapeutic drugs. 29 It was demonstrated that the addition of paclitaxel increased Akt activity, which was correlated with low level of cell death. 30 Similarly, induction of Akt by cisplatin was responsible for the observed chemotherapeutic resistance. 31 However, the exact mechanism of Akt activation leading to chemoresistance is unclear. 32 In the present study, treatment with doxorubicin or 5-FU had a notable effect on increasing the expression of p-Akt in SGC-7901 cells. The addition of 1 μM MK-2206 could effectively abrogate chemotherapyinduced Akt activation within 12 hours. It not only explains the synergism between MK-2206 and doxorubicin or 5-FU, but also raised a hypothesis that whether specific inhibition of induced Akt activation might augment the sensitivity of gastric cancer cells to conventional chemotherapy.
Previous researches have shown that the inhibition of PI3K/Akt could sensitize ovarian cancer cells to paclitaxel and increase the induction of apoptosis in colon cancer cells in combination with irinotecan. 30, 33 Molecule-targeted drugs such as LY294002 and rapamycin, which target other components of PI3K/Akt pathway, have been shown to be capable of restoring the chemotherapeutic sensitivity of gastric cancer cells in vitro and in vivo. [34] [35] [36] MK-2206, as a potent Akt inhibitor, showed a synergistic interaction in combination with anticancer agents in various cancer cells. The presence of MK-2206 could significantly increase the inhibition of proliferation of glioma cells, when treated with gefitinib, and hepatocarcinoma cells, when treated with doxorubicin. 26, 27 Similarly, in gastric cancer cells, the combined therapy of MK-2206 and chemotherapies showed a more powerful inhibition of proliferation than that of a single agent.
Investigations on the mechanisms underlying the combination effect of MK-2206 on anticancer agents also revealed that cell apoptosis played an important role in the induction of cell death. Although no significantly increased apoptosis was found in SGC-7901 cells at low concentrations of MK-2206 alone (0-12 μM), it could potentiate chemotherapy-induced apoptosis at concentrations as low as 1 μM. Caspases are a family of cell death proteases which are triggered in response to pro-apoptotic signals and play an essential role in the execution phase of apoptosis. [37] [38] [39] The activation of caspases during apoptosis results in the cleavage of critical cellular substrates, including PARP, and precipitating the dramatic morphological changes of apoptosis. Western blotting analysis revealed that the addition of 1 μM MK-2206 could increase the expression of cleaved caspase-3/7/9 and PARP by doxorubicin and 5-FU. Therefore, the addition of MK-2206 could effectively sensitize gastric cancer cells to chemotherapy by prompting cell apoptosis. Consistent with our observations, activation of caspase pathway was proved OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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MK-2206 inhibits gastric cancer to play an important role in the enhanced cell death induction in lapatinib-treated HCC70 breast cancer cells, erlotinibtreated non-small-cell lung cancer cell line NCL-H292, and etoposide-treated neuroblastoma, when co-treated with MK-2206. 13, 14 Hence, suppressed activity of caspase pathway may be involved in the reduced chemotherapeutic sensitivity of gastric cancer cells mediated by PI3K/Akt pathway.
Taken together, our result provides evidence that targeting PI3K/Akt pathway using MK-2206 is an efficient therapeutic strategy for gastric cancer. This treatment potentiates the antitumor effect of chemotherapeutics via the inhibition of activated Akt and induction of caspase pathway. Therefore, the combination of MK-2206 with chemotherapeutics may be helpful to overcome chemoresistance in gastric cancer. Further in vivo studies are warranted to confirm these findings.
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